{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:07:34Z","timestamp":1783750054943,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00904-9","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:01:43Z","timestamp":1693904503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Wanting","family":"Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1034-5179","authenticated-orcid":false,"given":"Sridurga","family":"Mithraprabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-9580","authenticated-orcid":false,"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-4007","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","volume":"103","author":"J Caers","year":"2018","unstructured":"Caers J, Garderet L, Kortum KM, O\u2019Dwyer ME, van de Donk N, Binder M, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103:1772\u201384.","journal-title":"Haematologica"},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35:18\u201330.","journal-title":"Leukemia"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cordon L, Cedena MT, Puig N, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol"},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"904_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0028-5","volume":"7","author":"P Moreau","year":"2017","unstructured":"Moreau P, Zamagni E. MRD in multiple myeloma: more questions than answers. Blood Cancer J. 2017;7:639.","journal-title":"Blood Cancer J"},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","volume":"26","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, et al. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020;26:e7\u2013e15.","journal-title":"Biol Blood Marrow Transplant"},{"key":"904_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"},{"key":"904_CR8","doi-asserted-by":"crossref","unstructured":"Krebs MG, Malapelle U, Andre F, Paz-Ares L, Schuler M.Thomas DM,et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol. 2022;8:1830\u20131839.","DOI":"10.1001\/jamaoncol.2022.4457"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/s41375-021-01339-6","volume":"35","author":"S Mithraprabhu","year":"2021","unstructured":"Mithraprabhu S, Chen M, Savvidou I, Reale A, Spencer A. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia. 2021;35:2771\u201383.","journal-title":"Leukemia"},{"key":"904_CR10","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","volume":"36","author":"JM Waldschmidt","year":"2022","unstructured":"Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, et al. Cell-free DNA for the detection of emerging treatment failure in relapsed\/ refractory multiple myeloma. Leukemia. 2022;36:1078\u201387.","journal-title":"Leukemia"},{"key":"904_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2023;41:1383\u201392.","journal-title":"J Clin Oncol"},{"key":"904_CR13","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.22.02114","volume":"41","author":"N van de Donk","year":"2023","unstructured":"van de Donk N. How we manage newly diagnosed multiple myeloma with circulating tumor cells. J Clin Oncol. 2023;41:1342\u20139.","journal-title":"J Clin Oncol"},{"key":"904_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25469-8","volume":"12","author":"KH Maclachlan","year":"2021","unstructured":"Maclachlan KH, Rustad EH, Derkach A, Zheng-Lin B, Yellapantula V, Diamond B, et al. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nat Commun. 2021;12:5172.","journal-title":"Nat Commun"},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","volume":"32","author":"G Guo","year":"2018","unstructured":"Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018;32:1838\u201341.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00904-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:03:27Z","timestamp":1700316207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00904-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00904-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}